Sartorius looks back on a very successful 2020 and expects further strong growth
USA - English
Outlook for the current year: sales projected to increase by 19 percent to 25 percent
Accelerated and greater ramp-up of production capacities in all geographies; CAPEX ratio of 15 percent expected for 2021
Group management raises sales target for 2025 to about 5 billion euros
Creation of more than 1,000 new jobs on average per year
News provided by
Share this article
Share this article
GOTTINGEN, Germany, Feb. 18, 2021 /PRNewswire/ The life science group Sartorius confirmed its preliminary figures for 2020 upon the release of its annual report. Group sales revenue surged by 30.2 percent to nearly 2,336 million euros in constant currencies (reported: +27.8 percent). Order intake
Protalix BioTherapeutics Completes Raise of Approximately $40 Million in Gross Proceeds
USA - English
Company, with its Commercialization Partner, Chiesi, poised to commercialize PRX-102
Additional data and milestones expected throughout 2021
News provided by
Share this article
Share this article
CARMIEL, Israel, Feb. 18, 2021 /PRNewswire/ Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx
® plant cell–based protein expression system, today announced it has completed a raise bringing in gross proceeds of approximately $40 million, before deducting the underwriting discount and estimated expenses of the offering. BofA Securities acted as book-running manager for the offering with Oppenheimer & Co. acting as co-manager.
Share this article
Share this article
TEL AVIV, Israel and RALEIGH, N.C., Feb. 18, 2021 /PRNewswire/ RedHill Biopharma Ltd. (Nasdaq: RDHL) ( RedHill or the Company ), a specialty biopharmaceutical company, today announced agreements with Cosmo Pharmaceuticals NV (SIX: COPN) ( Cosmo ) to manufacture two key products; RedHill s largest selling product in the U.S., Movantik
®, and RHB-204, currently in a Phase 3 U.S. study as a stand-alone, first-line orally-administered treatment for pulmonary nontuberculous mycobacteria (NTM) disease. Movantik is currently our biggest commercial product. This agreement strengthens our qualified supply base and capacity moving forward and solidifies our ongoing strategic relationship with Cosmo,
NuVasive to Present at the 41st Annual Cowen Health Care Conference
News provided by
Share this article
Share this article
SAN DIEGO, Feb. 18, 2021 /PRNewswire/ NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, announced today that management will present at the 41
st Annual Cowen Health Care Conference on Monday, March 1, 2021 at 11:40 a.m. ET / 8:40 a.m. PT.
A live webcast of the presentation will be available online from the Investor Relations page of the Company s website at www.nuvasive.com. A replay of the presentation will remain available on the website for 30 days after the live webcast.
, Lion s Mane Focus
, and Teen, available for purchase.
VANCOUVER, BC, Feb. 18, 2021 /PRNewswire/ - Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) ( MINDCURE or the Products ). Items can now be ordered from the
Company s website and are expected to begin shipping Feb. 23. Our supplements launch marks the beginning of MINDCURE s product sales division, which is a key milestone for the company this year. With it, we re promoting support across the spectrum of mental hygiene to the general public,
said Sacha Hebbert, Senior Product & Marketing Manager, MINDCURE. MINDCURE s nootropic and adaptogen products are safe, unique, and packed with all-natural ingredients specifically chosen to promote mental performance. We re eager to continue developing our product offerings to help in new and exciting ways.